What is Pharmacogenomics — and why does it matter?
Pharmacogenomics (PGx) explores how genetic variation influences an individual’s response to medicines – shaping drug safety, efficacy, and clinical outcomes. As healthcare moves toward precision medicine, PGx is becoming a critical tool for delivering the right drug, at the right dose, for
the right patient, at the right time.
Backed by national investment from Innovate UK and delivered through the Centre of Excellence for Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx), led by Prof Sir Munir Pirmohamed, as one of five work packages output, the CERSI-PGx Portal sits at the forefront of UK
healthcare innovation.
Led by Dr. Emma Magavern and Dr. Maria Tsakiroglou, Work package 3 CERSI-PGx brings together expertise from the University of Liverpool, Queen Mary University of London, and BPS to advance awareness in PGx and address a widely identified training gap.


